Corazon Sanders
Director/Board Member presso MOLECULAR TEMPLATES, INC.
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Corazon Dating Sanders is currently serving as a Director at AbGenomics International, Inc. Additionally, Sanders holds the position of Independent Director at Ultragenyx Pharmaceutical, Inc., Independent Non-Executive Director at BeiGene Ltd., Independent Director at Legend Biotech Corp., Independent Director at Molecular Templates, Inc., and Director at Altrubio, Inc. Previously, Sanders worked as a Director at Fred Hutchinson Cancer Research Center and Transcelerate Biopharma, Inc. Sanders also held the position of Senior Vice President & Global Head-PD Innovation at Genentech, Inc. From 2017 to 2018, Sanders served as the Executive Vice President-Development Operations at Juno Therapeutics, Inc.Sanders completed undergraduate and graduate studies at the University of the Philippines.
Sanders also obtained graduate and doctorate degrees from The Wharton School of the University of Pennsylvania.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
BEIGENE LTD
0.01% | 23/06/2023 | 86 847 ( 0.01% ) | 1 M $ | 31/03/2024 |
LEGEND BIOTECH CORP.
0.01% | 31/12/2022 | 19 376 ( 0.01% ) | 543 400 $ | 31/03/2024 |
| 30/06/2023 | 8 985 ( 0.01% ) | 419 510 $ | 31/03/2024 | |
| 27/10/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Corazon Sanders
| Società | Posizione | Inizio |
|---|---|---|
| MOLECULAR TEMPLATES, INC. | Director/Board Member | 19/12/2019 |
| LEGEND BIOTECH CORPORATION | Director/Board Member | 01/05/2020 |
| BEIGENE, LTD. | Director/Board Member | 24/08/2020 |
| ULTRAGENYX PHARMACEUTICAL INC. | Director/Board Member | 29/06/2021 |
AbGenomics International, Inc.
 AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | Director/Board Member | - |
Altrubio, Inc.
 Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | Director/Board Member | 01/03/2020 |
Precedenti posizioni note di Corazon Sanders
| Società | Posizione | Fine |
|---|---|---|
| JUNO THERAPEUTICS INC | Corporate Officer/Principal | 01/04/2018 |
Transcelerate Biopharma, Inc.
 Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Director/Board Member | 02/01/2016 |
Fred Hutchinson Cancer Research Center
 Fred Hutchinson Cancer Research Center Miscellaneous Commercial ServicesCommercial Services Fred Hutchinson Cancer Research Center is a non-profit organization which provides research and testing services. The company was founded in 1965 and is headquartered in Seattle, WA. | Director/Board Member | - |
| ░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Formazione di Corazon Sanders
| University of the Philippines | Graduate Degree |
| The Wharton School of the University of Pennsylvania | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| BEIGENE, LTD. | Health Technology |
| LEGEND BIOTECH CORPORATION | Health Technology |
| MOLECULAR TEMPLATES, INC. | Health Technology |
| Aziende private | 6 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
AbGenomics International, Inc.
AbGenomics International, Inc. Pharmaceuticals: MajorHealth Technology AbGenomics International, Inc. manufactures biopharmaceutical therapeutics. The firm produces therapeutics for the treatment of cancer and immune related inflammatory diseases. It also performs research discovery, preclinical and clinical development, as well as strategic planning for commercialization of its therapeutics. The company was founded by Rong-Hwa Lin in 2000 and is headquartered in Los Altos, CA. | Health Technology |
Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center Miscellaneous Commercial ServicesCommercial Services Fred Hutchinson Cancer Research Center is a non-profit organization which provides research and testing services. The company was founded in 1965 and is headquartered in Seattle, WA. | Commercial Services |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Health Technology |
Altrubio, Inc.
Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | Retail Trade |
- Borsa valori
- Insiders
- Corazon Sanders
